Variantyx Overview
Variantyx is an award-winning, technology-driven molecular diagnostics lab that offers innovative solutions in the genetic disorders, reproductive health, and precision oncology markets. Its proprietary whole genome analysis platform provides unparalleled diagnostic capabilities, enhances personalized treatment recommendations, shortens the time to diagnosis, and reduces healthcare costs. The company offers a wide variety of test options, ranging from targeted to comprehensive analyses. Targeted analyses focus on pre-curated panels of indication-relevant genes while comprehensive analyses consider all genes. All tests are performed on a whole genome platform. This makes it easy to start with a targeted analysis and automatically reflex up to a comprehensive analysis if the first test is non-diagnostic. No additional sample or sequencing is required.
Cumulative Funding Raised Over Time ($)
$36.0MApr 2024
$36.0MApr 2025
$39.0MDec 2017
$80.5MJan 2022
$85.5MJun 2014
$95.5MJun 2019
$121.5MMar 2021
$131.5MNov 2020
$151.5MOct 2022
$151.5MOct 2023
Latest News
Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0
Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase
Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis
Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint
Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $131.5M |
| Last funding | Undisclosed |
| Stage | D |
| Rounds | 10 |
| Investors | 12 |
Team Members
5
Employees: 201-500
Web & Social Links
| Website | www.variantyx.com |
| Careers | Careers page |
Locations
Chaim Levanon Street 55, Tel Aviv-Yafo, Israel
1671 Worcester Road, Framingham, MA 01701, United States
Photos & Videos
1 item(s)
Variantyx Business
Business models
B2B, B2B2C
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratoriesConsumersDemographics & FamilyWomenCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceTags (22)
biopharmaceuticalpharma-companiespersonalizationprecision-medicineoncologynon-invasivepregnancypersonalized-medicinecancerclinical-datamedical-technologiesgenetic-disordershospitalsgenomicsdoctorsclinicslaboratoriesdiagnosticswomen-healthrare-diseasesdigital-healthcareartificial-intelligenceGeographic Markets
United StatesEuropeVariantyx Financials
$131.5M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
D
Funding stage
10
Total rounds
12
Investors
Cumulative Funding Raised Over Time ($)
$36.0MApr 2024
$36.0MApr 2025
$39.0MDec 2017
$80.5MJan 2022
$85.5MJun 2014
$95.5MJun 2019
$121.5MMar 2021
$131.5MNov 2020
$151.5MOct 2022
$151.5MOct 2023
Private Equity Funding
Undisclosed Round
Apr 2025
Undisclosed
Peregrine Ventures
D Round
Apr 2024
$36M
Peregrine Ventures, Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners
Undisclosed Round
Oct 2023
Undisclosed
20/20 HealthCare Partners, Pitango HealthTech, Peregrine Ventures, New Era Capital Partners, Robert Bosch Venture Capital
Debt Financing
Oct 2022
$20M
Kreos Capital
C Round
Jan 2022
$41.5M
New Era Capital Partners (Lead)
,
20/20 HealthCare Partners, Robert Bosch Venture Capital, Pitango HealthTech, Peregrine Ventures
C Round
Mar 2021
$26M
Quark Venture (Lead)
,
Robert Bosch Venture Capital, IBM Ventures, Pitango HealthTech, 20/20 HealthCare Partners
Convertible Debt
Nov 2020
$10M
Undisclosed Investor(s), IBM
B Round
Jun 2019
$10M
Pitango HealthTech (Lead)
,
New Era Capital Partners
A Round
Dec 2017
$3M
F&F, 20/20 HealthCare Partners
Seed
Jun 2014
$5M
Founders
Variantyx Lifecycle
Cumulative Funding Raised Over Time
$36.0MApr 2024
$36.0MApr 2025
$39.0MDec 2017
$80.5MJan 2022
$85.5MJun 2014
$95.5MJun 2019
$121.5MMar 2021
$131.5MNov 2020
$151.5MOct 2022
$151.5MOct 2023
All Events
Undisclosed Round
Apr 2025
Undisclosed
Peregrine Ventures
D Round
Apr 2024
$36M
Peregrine Ventures, Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners
Undisclosed Round
Oct 2023
Undisclosed
20/20 HealthCare Partners, Pitango HealthTech, Peregrine Ventures, New Era Capital Partners, Robert Bosch Venture Capital
Debt Financing
Oct 2022
$20M
Kreos Capital
C Round
Jan 2022
$41.5M
New Era Capital Partners (Lead)
,
20/20 HealthCare Partners, Robert Bosch Venture Capital, Pitango HealthTech, Peregrine Ventures
C Round
Mar 2021
$26M
Quark Venture (Lead)
,
Robert Bosch Venture Capital, IBM Ventures, Pitango HealthTech, 20/20 HealthCare Partners
Convertible Debt
Nov 2020
$10M
Undisclosed Investor(s), IBM
B Round
Jun 2019
$10M
Pitango HealthTech (Lead)
,
New Era Capital Partners
A Round
Dec 2017
$3M
F&F, 20/20 HealthCare Partners
Seed
Jun 2014
$5M
Founders
Variantyx News
20 articlesVariantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0
Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase
Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis
Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint
Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round
growth-positive
Variantyx nabs $41.1M for tech-backed genomic analysis
Variantyx, a startup focused on precision medicine in genomic testing, has raised $41.5 million in a C-2 funding round. The company offers whole genome sequencing and an analytics platform to interpret the data. The funding will be used to expand market reach and focus on precision oncology. Precision genomics is becoming more prominent in healthcare, with companies like SeqOne Genomics and Deep Genomics also securing significant funding. Variantyx aims to help clinicians gain insights into patients genetic makeup for personalized treatment recommendations. The company plans to share new disruptive products in the pipeline.
InvestmentExpand
growth-positive
Variantyx Expands Into Prenatal, Cancer Testing
Variantyx, a genetic testing company, is expanding its menu to include prenatal and pan-cancer testing in the US. The company has launched its Genomic Unity Prenatal Analysis test, which analyzes amniotic fluid and blood from both parents to provide a genomic analysis of the fetus. They are also developing a genomic profiling test for cancer that will analyze tumor and normal tissue. The new assays will expand Variantyxs existing clinical testing menu for hereditary disease. The company has already been servicing prominent healthcare systems in the US. Variantyx has raised $20 million in a Series C financing round and plans to bring more sequencing in-house. They have secured reimbursement from more than half of commercial payers and are planning to use long and short reads for sequencing in the future.
CustomersExpand
Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders
Variantyx Launches Its WGS-Based Prenatal Test for High-Risk Pregnancies, Enters Women's Health Market
News: Variantyx Licenses IBM Technologies That Leverage AI for Somatic Analysis - Variantyx
growth-positive
Council Post: A Shorter Path To Genetic Testing Clarity
The article discusses the benefits of using whole genome sequencing (WGS) as a first-line approach in genetic testing for diagnosing diseases. It highlights the limitations of the traditional trial-and-error method and the potential of WGS to provide quicker and more accurate diagnoses. The adoption of WGS could significantly reduce the time and cost involved in genetic testing, benefiting patients and their families. However, the article also emphasizes the need for support and reimbursement from the health insurance industry to fully realize the potential of WGS-based testing. The impact on Variantyx, the company mentioned in the article, is growth-positive as it offers WGS-based testing services.
CustomersPartners
AMA Issues PLA Codes for Variantyx's Genomic Unity® Test Series
Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference
growth-positive
Genomic Testing Firm Variantyx Receives $7M Investment from Pitango Venture Capital
Clinical genomic testing company Variantyx has received a $7 million investment from Pitango Venture Capital. The funding is part of Pitangos new Pitango HealthTech Fund. Variantyx provides clinical genomic testing for screening and rare disease diagnostics. They have integrated their testing pipeline with FDNAs Face2Gene phenotyping technology and have launched a program for free whole genome sequencing-based testing for rare-disease patients.
Investment
Variantyx Launches Its RareDx Program, Providing Clinical Whole Genome Testing to Enrolled Patients
http://www.frontlinegenomics.com/opinion/17197/exomes-transition-test/
Variantyx Launches Variantyx Unity™, The All-In-One Genomic Diagnostic Test
Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis
growth-positive
Startup Variantyx Sees Itself As 'Virtual Lab' for Diagnostic Decision Support
Diagnostic decision support company Variantyx is betting on the trend towards whole-genome sequencing. The company introduced its cloud-based Genomic Intelligence platform, which automates the NGS testing process and offers clinically actionable suggestions, at the American Society of Human Genetics annual conference. Variantyx sells its service by subscription and offers a pay-per-test option. As an introductory offer, the company is providing no-cost second opinions to practicing clinicians for undiagnosed cases. Variantyx has been self-funded by its founders to date. The company aims to help clinicians sort through genomic data and believes that whole-genome sequencing is the future.
CustomersPartners
Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform
Variantyx Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 215 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
Variantyx Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 515119709 |
| Crunchbase | variantyx |
| Creator | Shmuel (Sam) Rausnitz |
| Creator email | shmuel.rausnitz@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-13T00:00:00.000Z |
| Created | 2016-09-26T00:00:00.000Z |
| Claimed | Yes |